4Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volumn:A useful marker of inflammatory bowel disease activity. Am J Gastroenterol, 2001, 96:776-781.
2Butzner JD, Parmar R, Bell CJ, Dalai V. Butyrateenema therapy stimulates mucosal repair in experimental colitis in the rat. Gut, 1996, 38: 568～573.
3Dieleman LA, Palmen MJ, Akol H, Bloemena E,Pena AS, Meuwissen SG, Van Rees EP. Chronicexperimental colitis induced by dextran sulphatesodium (DSS) is characterized by Th1 and Th2 cy-tokines. Clin Exp Immunol, 1998, 114: 385～391.
4Beagley KW, Black CA, Elson CO. Strain differences in susceptibility to TNBS-induced colitis(abstract). Gastroenterology, 1991, 100: A560.
5Ward M. The pathogenesis of Crohn's disease.Lancet, 1977, 2: 903-905.
6Shorter RG, Huizenga KA, Spencer RJ. A working hypothesis for the etiology and pathogenesisof nonspecific inflammatory bowel disease. Am JDig Dis, 1972, 17: 1024～ 1032.
7Kunin S, Gallily R. Recognition and lysis of altered-self cells by macrophages. I. Modification oftarget cells by 2, 4, 6-trinitrobenzene sulphonicacid. Immunology, 1983, 48: 265～272.
8Grisham MB, Volkmer C, Tso P, Yamada T. Metabolism of trinitrobenzene sulfonic acid by the ratcolon produces reactive oxygen species. Gastroenterology, 1991, 101: 540～547.
